Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Rolski, J. [1 ]
Grodzki, T. [2 ]
Schneider, C. P. [3 ]
Zatloukal, P. [4 ]
Reck, M. [5 ]
Aitin, E. [6 ]
Tan, E. H.
机构：
[1] Maria Sklodowska Curie Mem Inst Oncol, Krakow, Poland
[2] Reg Hosp Lung Dis, Szczecin, Poland
[3] Cent Clin Bad Berka, Bad Berka, Germany
[4] Pneumol Clin, Prague, Czech Republic
[5] Krankenhaus Grosshansdorf, Grosshansdorf, Germany
[6] Hosp Carlo Poma, Mantova, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71329-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6501
引用
收藏
页码：356 / 356
页数：1
相关论文
共 50 条
  • [1] Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)
    Tan, Eng-Huat
    Grodzki, Tomasz
    Schneider, Claus-Peter
    Zatloukal, Peter
    Reck, Martin
    Aitini, Enrico
    Rolski, Janusz
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S451 - S451
  • [2] Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
    Tan, E. H.
    Rolski, J.
    Grodzki, T.
    Schneider, C. P.
    Gatzemeier, U.
    Zatloukal, P.
    Aitini, E.
    Carteni, G.
    Riska, H.
    Tsai, Y. H.
    Abratt, R.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1249 - 1256
  • [3] Cisplatin (CDDP) plus vinorelbine (VRB) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Molecular correlates
    de las Penas, R.
    Provencio, M.
    Camps, C.
    Cobo, M.
    Massuti, B.
    Jimenez, U.
    Artal, A.
    Cardenal, F.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC)
    Saito, J
    Nakai, Y
    Saijo, Y
    Nukiwa, T
    Koinumaru, S
    Matsuura, Y
    Aso, N
    Yamane, Y
    Tsukamoto, T
    Sayama, T
    Nakabayashi, T
    LUNG CANCER, 2001, 31 (2-3) : 285 - 293
  • [5] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial
    Georgoulias, V.
    Ardavanis, A.
    Tsiafaki, X.
    Agelidou, A.
    Syrigos, K.
    Polyzos, A.
    Kakolyris, S.
    Kouroussis, Ch
    Androulakis, N.
    Chatzidaki, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 169
  • [6] Results of a Phase I/II Trial of Amrubicin (AMR) in Combination with Cisplatin (CDDP) as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hattori, Yoshihiro
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Negoro, Shunichi
    Hida, Toyoaki
    Takeda, Koji
    Masuda, Noriyuki
    Nakagawa, Kazuhiko
    Yokota, Soichiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S386 - S386
  • [7] Cisplatin (CDDP) plus vinorelbine (VRB) as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): molecular correlates
    Provencio, M.
    Blanco, R.
    Alberola, V.
    Delgado, J. R.
    Diz, P.
    Almenarez, J. A.
    Lopez-Vivanco, G.
    Gonzalez-Larriba, J. L.
    Martin, G.
    Rosell, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 384 - 384
  • [8] Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
    Seto, T.
    Ichinose, Y.
    Yamamoto, N.
    Kaira, K.
    Negoro, S.
    Hida, T.
    Takeda, K.
    Masuda, N.
    Yokota, S.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Cisplatin (CDDP) plus vinorelbine (NVB) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Retrospective analysis to improve the patient's convenience on day 8 NVB administration
    Provencio, M.
    de las Penas, R.
    Cobo, M.
    Massuti, B.
    Artal, A.
    Munoz-Langa, J. M.
    Garcia-Gomez, R.
    Sanchez-Ruiz, A.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
    Georgoulias, V
    Ardavanis, A
    Tsiafaki, X
    Agelidou, A
    Mixalopoulou, P
    Anagnostopoulou, O
    Ziotopoulos, P
    Toubis, M
    Syrigos, K
    Samaras, N
    Polyzos, A
    Christou, A
    Kakolyris, S
    Kouroussis, C
    Androulakis, N
    Samonis, G
    Chatzidaki, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2937 - 2945
12345